Claims
- 1. A compound of Formula (I):
- 2. The compound of claim 1, wherein A and B are different and N or CH; Y and Z are CH; X is O or S; R2, R4, R5, and R7 are each H; and R1, R3, R6 and R8 are selected from the group consisting of H, OH, methyl, methoxy, and acetoxy.
- 3. The compound of claim 1, wherein A and B are CH; X is O; Y is O; R2, R4, R5, and R7 are each H; and R1, R3, R6 and R8 are selected from the group consisting of H, OH, methyl, methoxy, and acetoxy.
- 4. The compound of claim 1, further comprising a pharmaceutically acceptable carrier.
- 5. A method of treating microbial infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I):
- 6. The method of claim 5, wherein A and B are different and N or CH; Y and Z are CH; X is O or S; R2, R4, R5, and R7 are each H; and R1, R3, R6, and R8 are selected from the group consisting of H, OH, methyl, methoxy, and acetoxy.
- 7. The method of claim 5, wherein A and B are CH; X is O; Y is O; R2, R4, R5, and R7 are each H; and R1, R3, R6, and R8 are selected from the group consisting of H, OH, methyl, methoxy, and acetoxy.
- 8. The method of claim 5, wherein the microbial infection is a Trypanosoma brucei rhodesiense infection or a Plasmodium falciparum infection.
- 9. A pharmaceutical formulation comprising:
(a) a compound of Formula (I): 21wherein: X is selected from the group consisting of O, S, and NR17, where R17 is hydrogen or lower alkyl; C1, C2, A, and Y are CH, N, NR17, O, or S, wherein C1 and C2 are the same or different; D1, D2, B, and Z are CH, N, or NR17 wherein D1and D2 are the same or different; provided that B, Z, or both B and Z are not present when A, Y, or both A and Y are O, S, or NR17; R13, R14, R15, R16, R1 and R8 are selected from the group consisting of H, lower alkyl, halogen, alkoxyl, aryloxyl, aralkoxy and hydroxyl; R3 and R8 are each independently selected from the group consisting of H, hydroxy, lower alkyl, cycloalkyl, aryl, aralkyl, alkoxyl, hydroxycycloalkyl, alkoxycycloalkyl, hydroxyalkyl, aminoalkyl, acyloxy, acetoxy, and alkylaminoalkyl; and R2, R4, R5 and R7 are each independently selected from the group consisting of H, lower alkyl, alkoxyalkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, aminoalkyl, and alkylaminoalkyl, or R2 and R4 together or R5 and R7 together represent a C2 to C10 alkyl, hydroxyalkyl, or alkylene, or R3 and R4together or R6 and R7 together are: 22wherein n is a number from 1 to 3, and R9 is H or —CONHR10NR11R12, wherein R10 is lower alkyl and R11 and R12 are each independently selected from the group consisting of H and lower alkyl; and (b) a pharmaceutically acceptable carrier.
- 10. The pharmaceutical formulation of claim 9, wherein A and B are different and N or CH; Y and Z are CH; X is O or S; R2, R4, R5, and R7 are each H; and R1, R3, R6, and R8 are selected from the group consisting of H, OH, methyl, methoxy, and acetoxy.
- 11. The pharmaceutical formulation of claim 9, wherein A and B are CH; X is O; Y is O; R2, R4, R5, and R7 are each H; and R1, R3, R6, and R8 are selected from the group consisting of H, OH, methyl, methoxy, and acetoxy.
RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Patent Application Serial No. 60/429,717, filed Nov. 27, 2002; the disclosure of which is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60429717 |
Nov 2002 |
US |